

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number
WO 2005/085253 A1

(51) International Patent Classification⁷: **C07D 487/04**,
A61K 31/505

(74) Agents: **ASAMURA**, Kiyoshi et al.; Room 331, New
Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku,
Tokyo 1000004 (JP).

(21) International Application Number:
PCT/JP2005/004266

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW.

(22) International Filing Date: 4 March 2005 (04.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2004-061555 5 March 2004 (05.03.2004) JP

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **TAISHO
PHARMACEUTICAL CO., LTD.** [JP/JP]; 24-1, Takada
3-chome, Toshima-ku, Tokyo 1708633 (JP).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **BISCHOFF**,
Francois, P. [BE/BE]; c/o Janssen Pharmaceutica N.V.,
Turnhoutseweg 30, B-2340 Beerse (BE). **KENNIS**,
Ludo, E., J. [BE/BE]; c/o Janssen Pharmaceutica N.V.,
Turnhoutseweg 30, B-2340 Beerse (BE). **BRAEKEN**,
Mirielle [BE/BE]; c/o Janssen Pharmaceutica N.V.,
Turnhoutseweg 30, B-2340 Beerse (BE). **DIELS**, **Gaston, S.,
M.** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhout-
seweg 30, B-2340 Beerse (BE). **NAKAZATO**, **Atsuro**
[JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada
3-chome, Toshima-ku, Tokyo 1708633 (JP).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: PYRROLOPYRIMIDINE DERIVATIVES



[1]

(57) Abstract: According to the present invention, there is provided an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastro-intestinal diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine derivative represented by the following formula [I] has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

WO 2005/085253 A1